Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT known ✓ | P43490 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 2/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL136776 | 0.79 | GRIN2D (0.52) | HIF1AAPPALDH1A1GRIN2DGRIN3B | |
| Iodide SCHEMBL9693917 | 0.77 | GRIN2D (0.50) | HIF1AAPPALDH1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL936436 | 0.77 | GRIN2D (0.50) | HIF1AAPPALDH1A1GRIN2DGRIN3B | |
| Bromide SCHEMBL6484310 | 0.77 | APP (0.54) | HIF1AAPPALDH1A1SNCAGRIN2D | |
| Hydrochloric Acid SCHEMBL9466518 | 0.76 | APP (0.49) | HIF1AAPPALDH1A1GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL5249711 | 0.76 | APP (0.49) | CYP1A2HIF1AAPPALDH1A1GRIN2D | |
| SCHEMBL7197162 | 0.73 | MEN1 (0.45) | CYP2C9CYP1A2CYP3A4CYP2C19VNN1 | |
| Hydrochloric Acid SCHEMBL905625 | 0.72 | FDPS (0.50) | CYP2C9CYP1A2CYP3A4CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL29710269 | 0.72 | FDPS (0.50) | CYP2C9CYP1A2CYP3A4CYP2C19HIF1A | |
| Hydrochloric Acid SCHEMBL18110356 | 0.71 | HIF1A (0.38) | CYP1A2CYP2C19HIF1AAPPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | ALLERGAN, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3277704-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016160362-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | ALLERGAN, INC. | 2016-10-06 | — | — | US | disclosed |
| EP-0150984-B1 | 6-(SUBSTITUTED) METHYLENEPENICILLANIC AND 6-(SUBSTITUTED) HYDROXYMETHYLPENICILLANIC ACIDS AND DERIVATIVES THEREOF | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0150984-A2 | 6-(Substituted) methylenepenicillanic and 6-(substituted) hydroxymethylpenicillanic acids and derivatives thereof | PFIZER INC. (US) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | CHP1, UACA, CRYAB | NAMPT 710/4885CYP2C9 288/4885CYP1A2 1072/4885 |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | CHP1, UACA, CRYAB | NAMPT 710/4885CYP2C9 288/4885CYP1A2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.